Business Wire

Solidigm Introduces the World’s Highest Capacity PCIe SSD for Massive Data Storage From Core to Edge

20.7.2023 18:00:00 EEST | Business Wire | Press release

Share

Solidigm, a leading global provider of innovative NAND flash memory solutions, is proud to announce another industry-first quad-level cell (QLC) solid-state storage drive (SSD) for the data center — the Solidigm D5-P5336. Offered in capacities from 7.68TB to 61.44TB, the Solidigm D5-P5336 makes it possible to store up to 6X more data in the same space compared to an all hard disk drive (HDD) array.1

"Modern workloads like AI and capabilities like 5G are rapidly reshaping the storage landscape,” said Greg Matson, VP of Strategic Planning and Marketing at Solidigm. “Businesses need storage in more places that is inexpensive, able to store massive data sets efficiently and access the data at speed. The D5-P5336 delivers on all three -- value, density and performance. With QLC, the economics are compelling -- imagine storing 6X more data than HDDs and 2X more data than TLC SSDs, all in the same space at TLC speed."

Built to handle massive amounts of data from the core to the edge, the read performance of the Solidigm D5-P5336 exceeds some of the latest cost-optimized triple-level cell (TLC) SSDs on the market today.2 Artificial intelligence (AI), machine learning (ML), content delivery networks, scale-out network attached storage (NAS), and object storage are all read-intensive workloads that continue to drive enormous volumes of data, regardless of where they reside.

Massive scalability and improved TCO across a range of configurations

With its high capacity enabling smaller storage footprints, Solidigm’s D5-P5336 enables a lower total cost of ownership and more sustainable infrastructure than all-TLC arrays, SAS HDD arrays, or hybrid arrays. Consider the following, based on a 100PB object storage solution deployment:

Solidigm

D5-P5336

Compare with:

All-TLC arrays

All-SAS HDD arrays

Hybrid arrays

TCO reduced by:

17%

47%

61%

Power and cooling reduced by:

Up to 1.25x

Up to 4.9x

Up to 6x

physical rack footprint reduced by:

1.9x

11.8x

14x

“For years there has been debate about endurance and reliability of SSDs, QLC in particular, but Solidigm might have ended that debate with the D5-P5336,” noted Avery Pham, VP Operations, VAST Data. “Any number of applications will see notable benefits from these drives from AI and machine learning to object storage.”

"Today, it is clear that the primary constraint for edge workloads is the limitation of bandwidth rather than latency,” said Doug Emby, VP of Sales and Business Development at Cheetah RAID Storage. “Solidigm’s D5-P5336 QLC SSDs offer an impressive combination of capacity, performance, and reliability as a solution to overcome this challenge. The seamless integration of these Solidigm QLC SSDs with Cheetah's high-performance servers makes them highly suitable for the efficient deployment of edge solutions."

The D5-P5336 is shipping now in E1.L form factor with up to 30.72TB, with subsequent availability extending to 61.44TB in both U.2 and E1.L later this year. In the first half of 2024, Solidigm will be shipping E3.S form factor with up to 30.72TB.

To learn more about the benefits of QLC, visit solidigm.com/qlc. Additionally, the D5-P5336 will be on display at the Solidigm booth (#107) at Flash Memory Summit in Santa Clara, Calif. August 8-10.

1 All-HDD capacity based on 12x 3.5” front load bays x 20TB = 240TB. HDD capacity does not factor in any over-provisioning required to meet storage performance needs. All-QLC capacity based on 24x U.2 front load bays x 61.44TB D5-P5336 = 1474TB. Max 2U U.2 based on HPE Proliant DL385 Gen 11 configuration. Max 2U 3.5” HDD bays based on Supermicro 2U SuperServer design.

2 Up to 34% higher throughput than entry TLC SSDs and 20% higher than mainstream TLC SSDs for CDN workload. Comparing 15.36TB Solidigm™ D5-P5336 with read BW of 7.5GB/sec to15.36TB Kioxia CD8-R with 5.6 GB/sec as entry TLC SSD and to 15.36TB Micron 7450 with 6.2GB/sec as mainstream TLC SSD. Workload based on representative customer profile. Test Configuration: Supermicro SYS-120U-TNR, Intel(R) Xeon(R) Gold 6354. Number of CPUs: 2, Cores per CPU: 18 (total 36), DRAM: DDR4 – 64GB, OS: Ubuntu 20.04.5 LTS Linux 5.15.0-67-generic. FIO 3.16.

ABOUT SOLIDIGM

Solidigm is a leading global provider of innovative NAND flash memory solutions. Solidigm technology unlocks data’s unlimited potential for customers, enabling them to fuel human advancement. Originating from the sale of Intel’s NAND and SSD business, Solidigm became a standalone U.S. subsidiary of semiconductor leader SK hynix in December 2021. Headquartered in Rancho Cordova, California, Solidigm is powered by the inventiveness of more than 2,000 employees in 13 locations worldwide. For more information, please visit solidigm.com and follow us on Twitter and LinkedIn. “Solidigm” is a trademark of SK hynix NAND Product Solutions Corp. (d/b/a Solidigm).

  • All products, computer systems, dates, and figures specified are preliminary based on current expectations and are subject to change without notice.
  • Differences in hardware, software, or configuration will affect actual performance.
  • Solidigm optimizations, for Solidigm compilers or other products may not optimize to the same degree for non-Solidigm products.
  • Solidigm technologies may require enabled hardware, software, or service activation.
  • Nothing herein is intended to create any express or implied warranty.
  • The products described in this document may contain design defects or errors known as “errata,” which may cause the product to deviate from published specifications. Currently characterized errata are available on request.
  • Your costs and results may vary.
  • © Solidigm. “Solidigm” is a trademark of SK hynix NAND Product Solutions Corp. (d/b/a Solidigm). Other names and brands may be claimed as the property of others.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Catherine Roberts
press@solidigm.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye